NCT03531073Completed
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
A Multicentre Observational Psoriatic Arthritis Cohort Study Addressing Real-life Outcomes of a Treat to Target Approach in Routine Clinical Practice.
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population. It is the central cohort for a planned Trials Within Cohorts (TWiCs) design which will test alternative therapies and interventions in embedded clinical trials comparing outcomes to those receiving "standard care" in the cohort.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 446 (actual)
- First submitted
- 8 Feb 2018
- Start date
- 18 Apr 2018
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University of Oxford
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT03531073
What you commit to
- Study type: Observational
- Participants enrolled: 446
- From 18 Apr 2018 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous treatment of arthritis with synthetic DMARDs (including methotrexate, leflunomide or sulfasalazine) or biologic DMARDs (including tumour necrosis factor (TNF), interleukin (IL)12/23 or IL17 inhibitor therapies) or targeted synthetic DMARDs (phosphodiesterase (PDE) 4 or Janus kinase (JAK) inhibitor therapies).
- Use of investigational therapies within 1 month or 5 biological half-lives of the baseline study visit(whichever is longer)
Other
- Women who are pregnant, nursing or planning pregnancy during the following 12 months.
Who the study is looking for
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female
- Aged 18 years or above.
- Clinical diagnosis of PsA based upon the Classification of PsA (CASPAR) criteria(23))
- Active PsA defined by ≥1 tender or ≥1 swollen joint or ≥1 enthesis (site of attachment of tendon to bone)
- Not previously received treatment with synthetic or biologic disease-modifying anti-rheumatic drugs (DMARDs) for their articular disease.
- In the Investigator's opinion, is able and willing to comply with all study requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford University Hospitals NHS Trust Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.